{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:51Z","timestamp":1794315411756,"version":"4.9.0"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763900"],"award-info":[{"award-number":["2024M763900"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["BX20230450"],"award-info":[{"award-number":["BX20230450"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471059"],"award-info":[{"award-number":["82471059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate comparative effectiveness of cyclosporine, interferon alfa\u20102a, and adalimumab for the prevention of uveitis relapse in Beh\u00e7et disease in real\u2010world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We emulated a target trial involving adult patients with Beh\u00e7et disease uveitis who initiated cyclosporine, interferon alfa\u20102a, or adalimumab between April 10, 2008, and August 1, 2024, and were observed up until September 10, 2024. We applied overlap weighting to balance patient characteristics across treatment groups and emulate randomization at baseline. The primary outcome was the annualized relapse rate of uveitis during treatment with study therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort comprised 716 cyclosporine users, 193 interferon alfa\u20102a users, and 103 adalimumab users. The estimated mean annualized relapse rate of uveitis was 0.95 (95% confidence interval [CI] 0.82\u20131.10) with cyclosporine, 0.52 (95% CI 0.40\u20130.69) with interferon alfa\u20102a, and 0.28 (95% CI 0.19\u20130.43) with adalimumab. Patients treated with cyclosporine experienced more relapses than those treated with adalimumab (incidence rate ratio [IRR] 3.36 [95% CI 2.23\u20135.05]; mean difference 0.66 [95% CI 0.48\u20130.85];\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) or interferon alfa\u20102a (IRR 1.81 [95% CI 1.37\u20132.4]; mean difference 0.42 [95% CI 0.22\u20130.62];\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). The relapse rate was higher with interferon alfa\u20102a than with adalimumab (IRR 1.86 [95% CI 1.16\u20132.97]; mean difference 0.24 [95% CI 0.05\u20130.43];\n                      <jats:italic>P<\/jats:italic>\n                      = 0.011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Beh\u00e7et disease, interferon alfa\u20102a was associated with a reduction in uveitis relapse compared with cyclosporine, whereas adalimumab demonstrated a stronger association with reduced relapse than interferon alfa\u20102a.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art43382-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43382","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:44:51Z","timestamp":1757925891000},"page":"438-448","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Real\u2010World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Beh\u00e7et Disease"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-3024","authenticated-orcid":false,"given":"Zhenyu","family":"Zhong","sequence":"first","affiliation":[{"name":"Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[{"name":"Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Xia","sequence":"additional","affiliation":[{"name":"Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiang","family":"Jing","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Lai","sequence":"additional","affiliation":[{"name":"Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cai","sequence":"additional","affiliation":[{"name":"Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-6619","authenticated-orcid":false,"given":"Peizeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Ophthalmology Medical Center, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, The First Affiliated Hospital of Chongqing Medical University  Chongqing China"},{"name":"The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2305712"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew486"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02629-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101216"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.208"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.056"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00301-1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key242"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080432"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1384026"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1439_22"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00194-2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699903"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.5584"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.11.021"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.03.058"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315960"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)34001-0"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-009-9301-3"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1815797"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0719-0"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181c307ce"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2016.1260466"},{"issue":"1","key":"e_1_2_6_31_1","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li F","year":"2019","journal-title":"Am J Epidemiol"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7819"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1214\/19-AOAS1282"},{"key":"e_1_2_6_34_1","article-title":"Provincial variations in catastrophic health expenditure and medical impoverishment in China: a nationwide population\u2010based study","volume":"31","author":"Jia Y","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1200"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.912906"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard\u20102024\u2013226113"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae585"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0597-x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2407586"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1184"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9029"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.43382","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:28:08Z","timestamp":1773008888000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/art.43382"],"URL":"https:\/\/doi.org\/10.1002\/art.43382","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"2025-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}